tirzepatide
Eli Lilly’s tirzepatide demonstrates efficacy in reducing sleep apnoea severity
April 18, 2024Research and Development Ear Nose & throat, Eli Lilly, clinical trial, sleep apnoea, tirzepatide
Eli Lilly has announced positive topline results from its SURMOUNT-OSA phase 3 trials which demonstrated that tizepatide injection (10mg or …
Eli Lilly shares data from two phase 3 tirzepatide studies
July 28, 2023Research and Development Eli Lilly, Obesity, clinical trial, tirzepatide, weight loss
Eli Lilly has announced results from its two phase 3 tirezepatide studies in adult patients with obesity or who are …
Lilly’s tirzepatide generates significant reductions in weight and blood sugar in type 2 diabetes patients
December 10, 2020Research and Development Eli Lilly, diabetes, tirzepatide
Eli Lilly has announced new data for its glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide, showing …
Latest content
Global coalition calls for stronger government action on COPD
September 18, 2026
Global health researchers call for more equitable partnerships
September 17, 2026
Liverpool launches £20m lab for infectious disease drug discovery
September 16, 2026
Circle Health Group expands into UK laboratory operations
September 15, 2026
